alcohol deterrents

Summary

Summary: Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism.

Top Publications

  1. ncbi Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents
    Helmut Niederhofer
    Christian Doppler Clinic, A 5020, Salzburg, Austria
    Drug Alcohol Rev 22:295-7. 2003
  2. ncbi Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment
    Barbara J Mason
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
    Eur Neuropsychopharmacol 13:469-75. 2003
  3. ncbi Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
    Carmen Bouza
    Agency for Health Technology Assessment, Madrid, Spain
    Addiction 99:811-28. 2004
  4. pmc Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase
    Jason P Schroeder
    Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Neuropsychopharmacology 35:2440-9. 2010
  5. ncbi The status of disulfiram: a half of a century later
    Jesse J Suh
    Treatment Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 26:290-302. 2006
  6. doi The effectiveness of continuing group psychotherapy for outpatients with alcohol dependence: 77-month outcomes
    Jee Wook Kim
    Department of Neuropsychiatry, Hangang Sacred Heart Hospital, Hallym University, Seoul, Korea
    Alcohol Clin Exp Res 36:686-92. 2012
  7. ncbi Medications for treating alcohol dependence
    Steven H Williams
    Psychology Service, Veterans Affairs Medical Center, Lebanon, Pennsylvania 17042, USA
    Am Fam Physician 72:1775-80. 2005
  8. ncbi Pharmacotherapy of alcohol dependence: a review of the clinical data
    Karl Mann
    Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
    CNS Drugs 18:485-504. 2004
  9. ncbi A critical review of pharmacoeconomic studies of acamprosate
    Flavio Poldrugo
    Office for Research and Innovative Projects on Alcohol, Other Addictions and Mental Health, Department of Psychiatry, University of Trieste, Via De Pastrovich 5 A, 34126 TRIESTE, Italy
    Alcohol Alcohol 40:422-30. 2005
  10. ncbi Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1
    George A Kenna
    Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA
    Am J Health Syst Pharm 61:2272-9. 2004

Detail Information

Publications153 found, 100 shown here

  1. ncbi Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents
    Helmut Niederhofer
    Christian Doppler Clinic, A 5020, Salzburg, Austria
    Drug Alcohol Rev 22:295-7. 2003
    ..In some cases, disulfiram may be an effective and well-tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of adolescent alcohol-dependent patients...
  2. ncbi Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment
    Barbara J Mason
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
    Eur Neuropsychopharmacol 13:469-75. 2003
    ..The safety of the two drugs in combination has been supported by two independent double-blind studies, and combination treatment may offer an advantage for some patients...
  3. ncbi Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
    Carmen Bouza
    Agency for Health Technology Assessment, Madrid, Spain
    Addiction 99:811-28. 2004
    ..To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence...
  4. pmc Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase
    Jason P Schroeder
    Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Neuropsychopharmacology 35:2440-9. 2010
    ..Our results suggest that disulfiram's efficacy in the treatment of cocaine addiction is associated with the inhibition of DBH and interference with the ability of environmental stimuli to trigger relapse...
  5. ncbi The status of disulfiram: a half of a century later
    Jesse J Suh
    Treatment Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 26:290-302. 2006
    ..Preliminary evidence also suggests that disulfiram treatment could be a viable treatment for cocaine dependence because it was shown to reduce cocaine use among nonalcoholic, cocaine-dependent patients...
  6. doi The effectiveness of continuing group psychotherapy for outpatients with alcohol dependence: 77-month outcomes
    Jee Wook Kim
    Department of Neuropsychiatry, Hangang Sacred Heart Hospital, Hallym University, Seoul, Korea
    Alcohol Clin Exp Res 36:686-92. 2012
    ..On that basis, a long-term comparative trial was performed with the main objective of evaluating the effectiveness of continuing group PT for outpatients with AD...
  7. ncbi Medications for treating alcohol dependence
    Steven H Williams
    Psychology Service, Veterans Affairs Medical Center, Lebanon, Pennsylvania 17042, USA
    Am Fam Physician 72:1775-80. 2005
    ..S. Food and Drug Administration for this indication, the anticonvulsant topiramate and several serotonergic agents (e.g., fluoxetine, ondansetron) have been shown in recent studies to increase abstinence rates and decrease drinking...
  8. ncbi Pharmacotherapy of alcohol dependence: a review of the clinical data
    Karl Mann
    Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
    CNS Drugs 18:485-504. 2004
    ..Pharmacotherapy should be used in association with appropriate psychosocial support and specific treatment provided for any underlying psychiatric comorbidities...
  9. ncbi A critical review of pharmacoeconomic studies of acamprosate
    Flavio Poldrugo
    Office for Research and Innovative Projects on Alcohol, Other Addictions and Mental Health, Department of Psychiatry, University of Trieste, Via De Pastrovich 5 A, 34126 TRIESTE, Italy
    Alcohol Alcohol 40:422-30. 2005
    ..This review assessed the published data on the cost-effectiveness of acamprosate for the treatment of alcohol dependence...
  10. ncbi Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1
    George A Kenna
    Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA
    Am J Health Syst Pharm 61:2272-9. 2004
    ..The neurobiological basis of alcohol dependence, established pharmacotherapies for alcohol dependence, pharmacotherapies under investigation, and obstacles to treatment are discussed...
  11. doi Disulfiram impairs the development of behavioural sensitization to the stimulant effect of ethanol
    Andrezza Kyunmi Kim
    Departamento de Psicobiologia Universidade Federal de São Paulo UNIFESP, Rua Napoleao de Barros 925, Sao Paulo, Sao Paulo, Brazil
    Behav Brain Res 207:441-6. 2010
    ..This study sought to analyze the influence of disulfiram on the development of behavioural sensitization to the stimulant effect of ethanol...
  12. ncbi An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence
    Avinash De Sousa
    Get Well Clinic and Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India
    Alcohol Alcohol 40:545-8. 2005
    ..To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice...
  13. doi [Pharmacology of disulfiram - an update]
    J Mutschler
    Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut fur Seelische Gesundheit, Mannheim
    Fortschr Neurol Psychiatr 76:225-31. 2008
    ..As an example we demonstrate a case, in which an acute neurological deficit was misjudged as a side effect of Disulfiram. Furthermore, the potential of Disulfiram as a promising treatment in addiction medicine will be discussed...
  14. ncbi New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence
    Falk Kiefer
    University of Heidelberg, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, CIMH, J5, D 68159 Mannheim, Germany
    Eur J Pharmacol 526:163-71. 2005
    ..New compounds are under investigation. This review discusses the neurobiological basis of alcohol addiction, pharmacological targets for relapse prevention treatment and pre-clinical and clinical results with the most promising drugs...
  15. ncbi Pharmacological approaches to the management of alcohol addiction
    G Addolorato
    Istituto di Medicina Interna, Universita Cattolica del Sacro Cuore, Roma
    Eur Rev Med Pharmacol Sci 6:89-97. 2002
    ..However, pharmacotherapy should not be considered as the only form of treatment but as an integrated part of a multimodal approach including psychological and social support...
  16. ncbi Disulfiram treatment for alcoholism in severe mental illness
    Kim T Mueser
    Department of Psychiatry, Dartmouth Medical School, Concord, NH, USA
    Am J Addict 12:242-52. 2003
    ..The results suggest disulfiram may be a useful adjunctive treatment for alcoholism in patients with severe mental illness and that controlled research is needed to evaluate its effects in this population...
  17. ncbi A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence
    Alan de Sousa
    Get Well Clinic and Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, India
    Alcohol Alcohol 39:528-31. 2004
    ..To compare the efficacy of naltrexone and disulfiram in preventing an alcoholic relapse in routine clinical practice in an Indian metropolis...
  18. ncbi New pharmacotherapies for alcohol dependence
    Robert Graham
    St Vincent s Hospital, Sydney, NSW, Australia
    Med J Aust 177:103-7. 2002
    ..Adjunctive psychosocial treatment with close follow-up is required for acamprosate and recommended for naltrexone. As yet, no studies have reported a reduction in mortality following the use of any pharmacotherapy for alcohol dependence...
  19. doi Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients
    Alexander Diehl
    Department of Psychiatry, Klinikum Braunschweig, Braunschweig, Germany
    Alcohol Alcohol 45:271-7. 2010
    ..To compare the long-term effectiveness of acamprosate (ACP) and disulfiram (DSF) in the treatment of alcohol dependence and their effectiveness in regard to patient characteristics, within a naturalistic outpatient treatment setting...
  20. doi Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment
    Márcia Fonsi Elbreder
    Alcohol and Drugs Research Unit Uniad, Rua Botucatu 394 Vila Clementino CEP 04023 061, Sao Paulo SP, Brazil
    Alcohol Alcohol 46:74-6. 2011
    ..To identify factors associated with retention in treatment of alcohol-dependent individuals and to compare treatment retention between men and women...
  21. ncbi Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment
    Henning Krampe
    Department of Anaesthesiology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Germany
    Curr Pharm Des 16:2076-90. 2010
    ....
  22. ncbi Safety issues concerning the use of disulfiram in treating alcohol dependence
    J Chick
    Department of Psychiatry, University of Edinburgh, Scotland
    Drug Saf 20:427-35. 1999
    ..Disulfiram can be viewed as a drug with a moderate record of adverse effects. Alcohol dependence, for which it can be a helpful treatment, is associated with a high morbidity and mortality...
  23. ncbi The use of disulfiram for alcohol-dependent patients and duration of outpatient treatment
    Márcia Fonsi Elbreder
    Department of Psychiatry, Federal University of Sao Paulo UNIFESP, Sao Paulo, Brazil
    Eur Arch Psychiatry Clin Neurosci 260:191-5. 2010
    ..Although disulfiram is an old medication, it seems that this drug can be useful for keeping alcohol-dependent patients under outpatient treatment...
  24. ncbi Paradigm to test a drug-induced aversion to ethanol
    E Garver
    Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Alcohol Alcohol 35:435-8. 2000
    ..This model should be of value in the testing of new agents that reduce aldehyde dehydrogenase levels for prolonged periods for their potential as an aversive treatment in alcoholism...
  25. ncbi [The role of the glutamatergic system in the pathogenesis and treatment of alcohol dependence]
    Karina Łukasik
    Zakład Farmakodynamiki Uniwersytetu Medycznego w Łodzi, Łódź
    Postepy Hig Med Dosw (Online) 64:534-43. 2010
    ..There are promising preclinical results of groups I and II metabotropic receptor antagonists. However, further studies are necessary to elucidate precisely their role in alcohol dependence...
  26. ncbi Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients
    L Annemans
    Vrije Universiteit Brussel, Brussels, Belgium
    Eur Addict Res 6:71-8. 2000
    ..A global anticipated net saving of 70 million BEF (1.74 million Euro) over 2 years was estimated for the Belgian health insurance...
  27. ncbi Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial
    Raymond F Anton
    Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston 29425, USA
    JAMA 295:2003-17. 2006
    ..Alcohol dependence treatment may include medications, behavioral therapies, or both. It is unknown how combining these treatments may impact their effectiveness, especially in the context of primary care and other nonspecialty settings...
  28. ncbi Treatment of alcohol-dependent outpatients with acamprosate: a clinical review
    B J Mason
    Department of Psychiatry and Behavioral Sciences, University of Miami/JMH Medical Center, Fla 33136, USA
    J Clin Psychiatry 62:42-8. 2001
    ..The drug's reliable effect on prolonging abstinence, in conjunction with an excellent safety profile, suggests that acamprosate may be useful for a broad range of patients with alcohol dependence...
  29. ncbi Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study
    Kee Namkoong
    Department of Psychiatry, Yonsei University College of Medicine, Seoul, South Korea
    Alcohol Alcohol 38:135-41. 2003
    ..A multi-centre, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and the safety of acamprosate over 8 weeks in Korean alcohol-dependent patients...
  30. ncbi Does disulfiram have a role in alcoholism treatment today?
    Richard K Fuller
    Addiction 99:21-4. 2004
  31. ncbi Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients
    Roel Verheul
    Department of Clinical Psychology, University of Amsterdam, Amsterdam, The Netherlands
    Psychopharmacology (Berl) 178:167-73. 2005
    ..However, acamprosate prevents lapses or relapses only in a minority of patients. An important question, therefore, is whether there is a specific subgroup of patients who respond particularly well to acamprosate...
  32. ncbi Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis
    H R Kranzler
    Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Alcohol Clin Exp Res 25:1335-41. 2001
    ..In the absence of studies that compare the effects of these medications, we used a meta-analytic approach to the literature to compare their efficacy in alcoholism treatment...
  33. ncbi Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial
    Fernando A Furieri
    Vitória Municipal Addiction Treatment Center, Vitoria, Espirito Santo, Brazil
    J Clin Psychiatry 68:1691-700. 2007
    ..This study examined the efficacy of a 28-day gabapentin treatment in reducing alcohol consumption and craving...
  34. ncbi Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome
    Henning Krampe
    Department of Psychiatry and Psychotherapy, Georg August University, and Max Planck Institute of Experimental Medicine, Goettingen, Germany
    Alcohol Clin Exp Res 30:86-95. 2006
    ..patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence.
  35. ncbi Combined therapy: what does acamprosate and naltrexone combination tell us?
    Falk Kiefer
    Department of Psychiatry, University Hospital of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
    Alcohol Alcohol 39:542-7. 2004
    ..It remains to be answered whether data justify the combination of both drugs in clinical practice...
  36. ncbi Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study
    Leonid S Shpilenya
    Narcological County Dispensary, Vasyleostrovsky District 4 th, Line V 0 2 3 2 5, St Petersburg, Russia
    Alcohol Clin Exp Res 26:340-6. 2002
    ..The present study was planned with the aim of investigating the effectiveness of metadoxine in the management of patients affected by acute ethanol intoxication...
  37. ncbi Metadoxine in the treatment of acute and chronic alcoholism: a review
    G Addolorato
    Institute of Internal Medicine, Catholic University of Rome, Italy
    Int J Immunopathol Pharmacol 16:207-14. 2003
    ..In this review the preclinical and clinical results obtained using metadoxine in acute and chronic alcohol intoxication are reported...
  38. ncbi New pharmacological approaches for the treatment of alcoholism
    Michael Soyka
    Private Hospital Meiringen, P O Box 612, CH 3860 Meiringen, Switzerland
    Expert Opin Pharmacother 7:2341-53. 2006
    ..Tricyclics have been found to be more effective than serotonin reuptake inhibitors in improving depressive symptoms in these patients...
  39. ncbi Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst
    Felice Nava
    Department of Addiction Medicine, Drug Abuse Unit Ser T, Hospital of Castelfranco Veneto, Via Ospedale, 18, 31033 Castelfranco Veneto Treviso, Italy
    J Psychoactive Drugs 38:211-7. 2006
    ..The maximum effects were observed in GHB-treated patients. The results of the present study suggest that GHB might act both as anticraving and cellular protector agent...
  40. ncbi [The pharmacologic treatment of the alcohol dependence]
    Luís André Castro
    Unidade de Pesquisa Clínica, Unidade de Pesquisa em Alcool e Drogas, Departamento de Psiquiatria, EMP UNIFESP, Brazil
    Rev Bras Psiquiatr 26:S43-6. 2004
    ..Ondansetron, has shown promise in the early-onset alcohol dependence but needs more extensive study. Topiramate (up to 300 mg per day) was more efficacious than placebo in the treatment of alcohol dependence...
  41. ncbi [Neurobiological mechanisms and pharmacological treatment options for alcohol craving]
    T Hillemacher
    Psychiatrische und Psychotherapeutische Klinik, Universitatsklinikum Erlangen, Germany
    Fortschr Neurol Psychiatr 75:26-32. 2007
    ..Besides, there are several promising candidate substances. Current investigations focus on a differentiated pharmacotherapy of alcohol dependence, including psychological and genetic factors...
  42. ncbi Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders
    Ismene L Petrakis
    Department of Psychiatry, Yale University, New Haven, Connecticut 06516, USA
    Biol Psychiatry 57:1128-37. 2005
    ..Disulfiram and naltrexone are approved by the Food and Drug Administration (FDA) for the treatment of alcoholism, but these agents have not been rigorously evaluated in dually diagnosed individuals...
  43. ncbi Trends in the adoption of medications for alcohol dependence
    Lori J Ducharme
    Institute for Behavioral Research, University of Georgia, Athens, GA 30602 2401, USA
    J Clin Psychopharmacol 26:S13-9. 2006
    ..Preliminary data suggest that the early adoption of acamprosate is following a similar pattern. Recommendations for addressing challenges to the diffusion of pharmacotherapies for alcohol dependence are presented...
  44. pmc Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention
    Young Chul Jung
    Department of Psychiatry, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
    Yonsei Med J 47:167-78. 2006
    ..In addition, novel medications are being investigated to assess their efficacy in preventing relapse and increasing abstinence...
  45. ncbi Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism
    Falk Kiefer
    Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health CIMH, University of Heidelberg, J5, 68159 Mannheim, Germany
    J Psychiatr Res 39:545-51. 2005
    ..Moreover, there are hints for an interaction between pharmacological anti-craving treatment, plasma concentration of leptin, and abstinence duration...
  46. ncbi Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
    Falk Kiefer
    Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
    Biol Psychiatry 60:74-6. 2006
    ..We examined the relationship between efficacy of pharmacological anticraving treatment and HPA axis activity in the relapse prevention treatment of alcoholism...
  47. ncbi [Maintaining abstinence after alcohol detoxification]
    Philippe Batel
    Traitement ambulatoire des maladies de l alcool, Hopital Beaujon, Clichy
    Rev Prat 56:1100-6. 2006
    ....
  48. ncbi Alcoholism and suicidal behavior: a clinical overview
    L Sher
    Division of Neuroscience, Department of Psychiatry, Columbia University, New York, NY 10032, USA
    Acta Psychiatr Scand 113:13-22. 2006
    ..The purpose of this paper was to provide a clinical review of the literature on the relation of alcoholism to suicidal behavior...
  49. ncbi Choosing the right medication for the treatment of alcoholism
    Helen M Pettinati
    Department of Psychiatry, University of Pennsylvania, Treatment Research Center, 3900 Chestnut Street, Philadelphia, PA 19104 6178, USA
    Curr Psychiatry Rep 8:383-8. 2006
    ..This report reviews the latest innovations in pharmacotherapy for the treatment of alcohol dependence, focusing on FDA-approved medications presently available to the treatment community...
  50. ncbi Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice
    Christopher M Doran
    School of Population Health, School of Economics, University of Queensland, Mayne Medical Building, Herston Road, Herston QLD 4006, Australia
    Addict Behav 31:1947-58. 2006
    ..To collect data on the behaviours associated with the prescription of pharmacotherapies (bupropion, acamprosate and naltrexone) for nicotine and alcohol dependence in Australian clinical practice...
  51. ncbi Pharmacotherapy of alcohol use disorders
    Alessandra Buonopane
    Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut, USA
    Subst Use Misuse 40:2001-20, 2043-8. 2005
    ..An overview of the serotonergic agents is also provided. Finally, future directions, including new medications and some clinical strategies that show promise but are not yet used extensively clinically, are mentioned...
  52. ncbi Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India
    Debasish Basu
    Drug De addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Am J Addict 14:381-95. 2005
    ..Logistic regression analysis showed that both family/social support and acamprosate appeared to contribute modestly toward explaining the variance in short-term outcome...
  53. ncbi Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms
    Markus Heilig
    National Institute on Alcohol Abuse and Alcoholism NIH DHHS, 10 Center Drive, 10 1E 5334 Bethesda, MD 20892 1610, United States
    Pharmacol Ther 111:855-76. 2006
    ..Once novel treatments are developed, the field faces a major challenge to assure their delivery to patients...
  54. ncbi Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler
    Henry R Kranzler
    University of Connecticut School of Medicine, Farmington, CT, USA
    Drugs 66:1753-4. 2006
  55. pmc The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders
    Aron N Starosta
    University of Pennsylvania, PA 19104, USA
    J Psychiatr Pract 12:80-9. 2006
    ..This paper describes these components and discusses how the empirical support for each component is linked to the enhancement of medication compliance and the improvement of treatment outcomes...
  56. ncbi Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
    Sheila A Doggrell
    School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia
    Expert Opin Pharmacother 7:2169-73. 2006
    ..In COMBINE, this percentage was high in the group having medical management and placebo pills, and naltrexone or additional behavioural therapy only had modest additional effects...
  57. ncbi Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy
    Gerald F X Feeney
    Alcohol and Drug Assessment Unit, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia
    Alcohol Alcohol 41:321-7. 2006
    ..To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone or acamprosate used singly or in combination, in a 12-week outpatient cognitive behavioural therapy (CBT) programme for alcohol dependence...
  58. ncbi [Pharmacological relapse prevention in alcohol and tobacco dependence]
    A Diehl
    Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut fur Seelische Gesundheit, J5, 68159, Mannheim, Germany
    Internist (Berl) 48:79-84, 86-8. 2007
    ..A specific application of these substances will optimise the outcome for alcohol and tobacco dependent patients...
  59. ncbi Preclinical and clinical pharmacology of alcohol dependence
    Sophie Tambour
    Unité de Recherche en Psychologie Expérimentale et Neurosciences Cognitives URPENC, Universite de Liege, Boulevard du Rectorat 5 B32, B 4000 Liege, Belgium
    Fundam Clin Pharmacol 21:9-28. 2007
    ..These new drugs in the field of alcohol pharmacotherapy are also discussed, together with their mechanisms of action...
  60. doi From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap
    Christopher W Shea
    Fr Martin s Ashley, Havre de Grace, Maryland 21078, USA
    South Med J 101:179-85. 2008
    ..Pharmacotherapy represents a valuable component of treatment and should be combined with psychosocial and behavioral interventions to address the multifactorial nature of AD in individuals with this disease...
  61. ncbi Acamprosate
    Barbara J Mason
    Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida 33136, USA
    Recent Dev Alcohol 16:203-15. 2003
  62. ncbi [Pharmacological review of alcoholic dependence treatment]
    Leandro Oural
    Hospital Alvarez
    Vertex 19:512-21. 2008
    ..We will also refer to topiramate, which is being studied for this indication...
  63. doi Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Kylie Richardson
    Central Clinical School of Medicine, University of Sydney, NSW, Australia
    Addiction 103:953-9. 2008
    ..To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the treatment of alcohol dependence...
  64. doi The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials
    James L Snyder
    Penn State Harrisburg, Middletown, Pennsylvania 17057, USA
    Am J Drug Alcohol Abuse 34:449-61. 2008
    ..There was insufficient data available to ascertain the efficacy of naltrexone and acamprosate over prolonged periods of time, or the effectiveness of the medications relative to each other...
  65. ncbi A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone
    Barbara J Mason
    Division of Substance Abuse, Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL, USA
    Neuropsychopharmacology 27:596-606. 2002
    ..A complete absence of negative interactions on measures of safety and cognitive function supports the absence of a contraindication to co-administration of acamprosate and naltrexone in clinical practice...
  66. ncbi [Long-term treatment of alcohol dependance]
    Louis Philippe Fideli
    Psychiatrie, CHU Louis Mourier, 178, rue des Renouillers, 92700 Colombes, France
    Gastroenterol Clin Biol 26:B169-73. 2002
  67. ncbi Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder
    Ismene L Petrakis
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
    Biol Psychiatry 60:777-83. 2006
    ....
  68. ncbi Addiction medicine for the primary care physician
    W H Yarborough
    University of Oklahoma, College of Medicine, Tulsa Campus, Department of Internal Medicine, 4502 E. 41st Street, Tulsa, OK 74135-2512, USA
    J Okla State Med Assoc 94:499-506. 2001
    ..Finally a look at parity for addiction treatment with a discussion of the cost and the benefits to society are also outlined...
  69. ncbi Pharmacologic approaches to the management of alcoholism
    R F Anton
    Alcohol Research Center, Medical University of South Carolina, Charleston 29425, USA
    J Clin Psychiatry 62:11-7. 2001
    ..This article will discuss animal and clinical studies of the opioid antagonists (primarily naltrexone), acamprosate, and disulfiram. The side effects and treatment recommendations for each drug will also be reviewed...
  70. ncbi Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment
    G Rubio
    Psychiatric Service, 12 de Octubre University Hospital, Madrid, Spain
    Alcohol Alcohol 36:419-25. 2001
    ..There were non-significant trends for the naltrexone group to comply better with medication, to stay in the study longer, and to show greater improvement over baseline in serum GGT...
  71. ncbi Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials
    J A Boening
    Department of Psychiatry, Addiction Medicine, University of Wuerzburg, Germany
    Alcohol Clin Exp Res 25:127S-131S. 2001
    ..Wiesbeck; and (6) Methodology and behavioral therapy of the U.S. acamprosate study, by Barbara J. Mason...
  72. doi [Alcohol dependence: diagnosis and treatment]
    P Perney
    Service d Addictologie, CHU Caremeau, 30029 Nimes Cedex 9, France
    Rev Med Interne 29:297-304. 2008
    ..5 million patients in France. A review about alcohol dependence is warranted, not only as prevalence of this disease is high, but also because of recent significant improvement in caring for these patients...
  73. ncbi Physicians' opinions about medications to treat alcoholism
    Tami L Mark
    Medstat, Washington, DC 20008, USA
    Addiction 98:617-26. 2003
    ..This paper examines physicians' opinions about and use of two alcoholism medications currently approved in the US--disulfiram and naltrexone--and one alcoholism medication--acamprosate--that might be approved...
  74. doi Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes
    Susanne Rösner
    IFT, Institut für Therapieforschung, Munich, Germany
    J Psychopharmacol 22:11-23. 2008
    ..Benefits in the treatment of alcohol dependence might be optimized by matching the efficacy profiles of specific antidipsotropics with the motivational status of alcohol-dependent patients...
  75. ncbi Recent advances in the pharmacotherapy of alcoholism
    Hugh Myrick
    Alcohol Research Center, Medical University of South Carolina Department of Psychiatry and Behavioral Sciences, 67 President Street, Charleston, SC 29425, USA
    Curr Psychiatry Rep 6:332-8. 2004
    ..Data on naltrexone, acamprosate, and topiramate will be highlighted. In addition, data concerning the use of serotonin reuptake inhibitors in subtypes of alcoholism and the use of combination pharmacotherapy will be reviewed...
  76. ncbi The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics
    Wendy Ooteman
    Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands
    Eur Neuropsychopharmacol 17:558-66. 2007
    ..It is hypothesized that naltrexone exerts its effects primarily on cue-induced craving and neuroendocrine cue reactivity, whereas acamprosate exerts its effect primarily on autonomic nervous system reactions to alcohol-related cues...
  77. ncbi Naltrexone and disulfiram in patients with alcohol dependence and current depression
    Ismene Petrakis
    Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven Campus, West Haven, CT 06516, USA
    J Clin Psychopharmacol 27:160-5. 2007
    ..In particular, the effect of these medications on alcohol use outcomes and on specific psychiatric symptoms is still unknown in patients with the most common co-occurring disorder, major depression...
  78. ncbi Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective
    Michael Soyka
    Psychiatric Hospital, University of Munich, Munich, Germany
    Am J Addict 12:S69-80. 2003
    ..Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability...
  79. ncbi Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland
    Caroline Buri
    University Hospital of Psychiatry Bern, Bolligenstrasse 111, 3000 Bern 60, Switzerland
    Alcohol Alcohol 42:333-9. 2007
    ..There remains, however, a paucity of studies with sufficient external validity in which the effectiveness of pharmacotherapy in clinical practice is investigated. This study aimed to make a contribution to close this gap in research...
  80. ncbi Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence
    John Littleton
    Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, KY 40546 0236, USA
    Am J Addict 12:S3-11. 2003
    ....
  81. ncbi [Drug therapy of alcohol dependence--a critical review]
    Mikko Salaspuro
    Biomedicum Helsinki, Päihdelääketieteen tutkimusyksikkö PL 63, 00014 Helsingin yliopisto
    Duodecim 119:2503-7. 2003
  82. ncbi Effect of the combination of naltrexone and acamprosate on alcohol intake in mice
    Sung Gon Kim
    Department of Psychiatry, School of Medicine, Pusan National University, Pusan, Korea
    Psychiatry Clin Neurosci 58:30-6. 2004
    ..When combined with naltrexone, acamprosate reduced alcohol consumption across both doses of naltrexone. This effect was sensitive to both dose and number of days of exposure to the naltrexone/acamprosate combination...
  83. ncbi Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers
    Lutz G Schmidt
    Department of Psychiatry, Johannes Gutenberg University Mainz, Untere Zahlbacher Str 8, 55131 Mainz, Germany
    Alcohol Alcohol 42:241-6. 2007
    ..To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al., 1997)...
  84. ncbi Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone
    Falk Kiefer
    Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Germany
    Addict Biol 13:124-9. 2008
    ..It is discussed whether especially these subjects should be targeted for pharmacological relapse prevention treatment with naltrexone...
  85. ncbi Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching
    Colin Brewer
    The Stapleford Centre, London, United Kingdom
    Subst Abus 24:157-73. 2003
    ..Supervised or depot naltrexone acts similarly in opiate dependence. We discuss the concept of antagonist-assisted abstinence...
  86. ncbi New therapies for alcohol dependence open options for office-based treatment
    Bridget M Kuehn
    JAMA 298:2467-8. 2007
  87. pmc A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkers
    Scott E Lukas
    Behavioral Psychopharmacology Research Laboratory MIC, Mail Stop 319 McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 226:65-73. 2013
    ..The present study was conducted in nontreatment-seeking heavy drinkers to assess the safety and efficacy of 4 weeks of kudzu extract in an outpatient setting...
  88. doi The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats
    Rui Ting Wen
    National Institute on Drug Dependence, Peking University, Beijing, China
    Alcohol Clin Exp Res 36:2157-67. 2012
    ..Thus, it was of interest to determine whether PDE4 was involved in the regulation of alcohol use and abuse...
  89. ncbi [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence]
    Przemysław Bieńkowski
    Zaklad Farmakologii i Fizjologii Ukladu Nerwowego IPiN w Warszawie Kierownik
    Psychiatr Pol 47:117-26. 2013
    ..The aim of the present article is to review the basic pharmacological features of naltrexone and its use in the treatment of alcohol dependence...
  90. doi New pharmacological treatment strategies for relapse prevention
    Rainer Spanagel
    Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, 68159 Mannheim, Germany
    Curr Top Behav Neurosci 13:583-609. 2013
    ..However, it will still be several years before the majority of the "treatment-seeking population" will benefit from those developments...
  91. pmc Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy
    Maziyar Amini
    Department of Gastroenterology and Hepatology, Loma Linda University Medical Center, 11234 Anderson Street, 1556, Loma Linda, CA 92354, United States
    World J Gastroenterol 16:4905-12. 2010
    ....
  92. pmc The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study
    Gary A Zarkin
    RTI International, Research Triangle Park, NC 27709, USA
    Med Care 48:396-401. 2010
    ..Policy makers, patients, and nonalcohol-dependent individuals may be concerned not only with alcohol treatment costs but also with the effect of alcohol interventions on broader social costs and outcomes...
  93. ncbi Nursing research and alcohol problems: learning from recent history?
    Maurice Dongier
    McGill University, Montreal, Quebec, Canada
    Can J Nurs Res 35:13-22. 2003
  94. ncbi The anti-craving taurine derivative acamprosate: failure to extinguish morphine conditioned place preference
    M Foster Olive
    Ernest Gallo Clinic and Research Center, Department of Neurology, University of California at San Francisco, California, USA
    Adv Exp Med Biol 526:481-4. 2003
  95. ncbi New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
    Christopher M Doran
    Med J Aust 179:218. 2003
  96. ncbi Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain
    M al Qatari
    Pharmacology Group of Kings College, London, United Kingdom
    Alcohol Clin Exp Res 25:1276-83. 2001
    ..The results are, however, compatible with other inhibitory effects on NMDA receptor function...
  97. doi Acamprosate modulates alcohol-induced hippocampal NMDA receptors and brain microsomal Ca2+-ATPase but induces oxidative stress in rat
    Ali Metehan Calişkan
    Department of Physiciatry, Medical Faculty, Suleyman Demirel University, Isparta, Turkey
    J Membr Biol 237:51-8. 2010
    ..Oxidative stress has been proposed to explain the biological side effects of experimental alcohol intake. Acamprosate and alcohol-induced oxidative stress decreased brain antioxidant vitamins in the alcoholic rats...
  98. ncbi Potential neuroprotective effects of acamprosate
    George F Koob
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California, USA
    Alcohol Clin Exp Res 26:586-92. 2002
    ..Siggins; (3) Acamprosate and glutamate during ethanol withdrawal, by Philippe De Witte; (4) Clinical evidence of protective CNS effects of acamprosate in alcohol-dependent individuals, by Barbara J. Mason...
  99. ncbi Advances in the use of naltrexone: an integration of preclinical and clinical findings
    STEPHANIE S O'MALLEY
    Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Recent Dev Alcohol 16:217-45. 2003
    ..Ultimately, these lines for research promise to provide critical information that can be used to maximize the efficacy of naltrexone for treating alcoholism...
  100. ncbi OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach
    H Ehrenreich
    Department of Psychiatry, Georg August University, Gottingen, Germany
    Eur Arch Psychiatry Clin Neurosci 247:51-4. 1997
    ....
  101. ncbi [Acute encephalopathy and polyneuropathy from disulfiram: toxicity and interactions]
    A Berger
    Therapie 57:505-7. 2002

Research Grants91

  1. Medication Development for Protracted Abstinence in Alcoholism
    Barbara Mason; Fiscal Year: 2009
    ..abstract_text> ..
  2. Medication Development for Protracted Abstinence in Alcoholism
    Barbara Mason; Fiscal Year: 2008
    ..abstract_text> ..
  3. MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCO
    Barbara Mason; Fiscal Year: 2003
    ..abstract_text> ..
  4. MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCO
    Barbara Mason; Fiscal Year: 2001
    ..abstract_text> ..
  5. MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCO
    Barbara Mason; Fiscal Year: 2000
    ..abstract_text> ..
  6. MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCO
    Barbara Mason; Fiscal Year: 1999
    ..abstract_text> ..
  7. Gabapentin Treatment of Cannabis Dependence
    Barbara Mason; Fiscal Year: 2009
    ....
  8. Pharmacological Treatment of Cannabis Withdrawal and Dependence
    Barbara J Mason; Fiscal Year: 2010
    ..The development of vofopitant as a novel medication for CD may have major public health benefits and is highly significant for the mission of NIDA. ..
  9. Gabapentin Treatment of Cannabis Dependence
    Barbara J Mason; Fiscal Year: 2010
    ....
  10. Medication Development for Protracted Abstinence in Alcoholism
    Barbara Mason; Fiscal Year: 2005
    ..abstract_text> ..
  11. Medication Development for Protracted Abstinence in Alcoholism
    Barbara Mason; Fiscal Year: 2007
    ..abstract_text> ..
  12. Medication Development for Protracted Abstinence in Alcoholism
    Barbara Mason; Fiscal Year: 2006
    ..abstract_text> ..
  13. MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCO
    Barbara Mason; Fiscal Year: 2002
    ..abstract_text> ..
  14. Mecamylamine for the Treatment of Alcohol Dependence
    Ismene Petrakis; Fiscal Year: 2009
    ..We will also evaluate smoking use outcomes and use this study as a platform to conduct future studies. This is the first study conducted to evaluate mecamylamine as a potential pharmacotherapeutic agent for alcohol dependence. ..
  15. RESEARCH TRAINING FELLOWSHIP IN SUBSTANCE ABUSE
    Ismene Petrakis; Fiscal Year: 2007
    ..At the conclusion of training, applicants will be well suited for independent careers in translational or intervention research in the field of addiction. ..
  16. Translational Neuroscience Research in Alcoholism
    Ismene Petrakis; Fiscal Year: 2008
    ..At the conclusion of training, applicants will be well suited for independent careers in translational research in the field of alcoholism. ..
  17. RESEARCH TRAINING FELLOWSHIP IN SUBSTANCE ABUSE
    Ismene Petrakis; Fiscal Year: 2008
    ..At the conclusion of training, applicants will be well suited for independent careers in translational or intervention research in the field of addiction. ..
  18. Mecamylamine for the Treatment of Alcohol Dependence
    Ismene L Petrakis; Fiscal Year: 2010
    ..We will also evaluate smoking use outcomes and use this study as a platform to conduct future studies. This is the first study conducted to evaluate mecamylamine as a potential pharmacotherapeutic agent for alcohol dependence. ..
  19. Translational Neuroscience Research in Alcoholism
    Ismene Petrakis; Fiscal Year: 2007
    ..At the conclusion of training, applicants will be well suited for independent careers in translational research in the field of alcoholism. ..
  20. Mecamylamine for the Treatment of Alcohol Dependence
    Ismene Petrakis; Fiscal Year: 2008
    ..We will also evaluate smoking use outcomes and use this study as a platform to conduct future studies. This is the first study conducted to evaluate mecamylamine as a potential pharmacotherapeutic agent for alcohol dependence. ..
  21. CLINICAL TRIALS NETWORK: NEW ENGLAND NODE
    Kathleen Carroll; Fiscal Year: 2005
    ....
  22. Computer-based Training in Cognitive Behavioral Therapy: Web-based delivery of CB
    Kathleen M Carroll; Fiscal Year: 2011
    ....
  23. Maximizing CBT's Efficacy with Medication & CM
    Kathleen Carroll; Fiscal Year: 2009
    ..Variables assessing theoretical mechanisms of action will be assessed monthly during treatment. ..
  24. Maximizing Effectiveness of Cognitive Behavior Therapy and Contingency Management
    Kathleen Carroll; Fiscal Year: 2007
    ..Study treatments will last 12 weeks. Primary outcomes will be percent days abstinent and results of urine toxicology screens. ..
  25. Maximizing CBT's Efficacy with Medication & CM
    Kathleen Carroll; Fiscal Year: 2007
    ..Variables assessing theoretical mechanisms of action will be assessed monthly during treatment. ..
  26. CLINICAL TRIALS NETWORK: NEW ENGLAND NODE
    Kathleen Carroll; Fiscal Year: 2007
    ....
  27. CLINICAL TRIALS NETWORK: NEW ENGLAND NODE
    Kathleen Carroll; Fiscal Year: 2008
    ....
  28. Computer-Based Training in Cognitve Behavioral Therapy
    Kathleen Carroll; Fiscal Year: 2002
    ..The patients' ability to demonstrate coping skills through a role-play evaluation will be a secondary outcome. A six-month follow-up will assess durability and/or delayed emergence of effects. ..
  29. Computer-Based Training in Cognitve Behavioral Therapy
    Kathleen Carroll; Fiscal Year: 2007
    ..abstract_text> ..
  30. Maximizing CBT's Efficacy with Medication & CM
    Kathleen Carroll; Fiscal Year: 2006
    ..Variables assessing theoretical mechanisms of action will be assessed monthly during treatment. ..
  31. PSYCHOTHERAPY OF SUBSTANCE USE DISORDERS
    Kathleen Carroll; Fiscal Year: 2008
    ..To maximize the effectiveness and durability of CM for abstinence, we will evaluate the benefit of integrating CM with skills training specifically designed to reduce drop-off of CM's benefits. ..
  32. PSYCHOTHERAPY OF SUBSTANCE USE DISORDERS
    Kathleen Carroll; Fiscal Year: 2007
    ..To maximize the effectiveness and durability of CM for abstinence, we will evaluate the benefit of integrating CM with skills training specifically designed to reduce drop-off of CM's benefits. ..
  33. Maximizing CBT's Efficacy with Medication & CM
    Kathleen Carroll; Fiscal Year: 2008
    ..Variables assessing theoretical mechanisms of action will be assessed monthly during treatment. ..
  34. Computer-Based Training in Cognitve Behavioral Therapy
    Kathleen Carroll; Fiscal Year: 2008
    ..abstract_text> ..
  35. CLINICAL TRIALS NETWORK: NEW ENGLAND NODE
    Kathleen Carroll; Fiscal Year: 2006
    ....
  36. Diffusion, Adoption, and Implementation of Pharmacotherapies in Alcohol Tx
    AMANDA ABRAHAM; Fiscal Year: 2007
    ..This information will be relevant to treatment providers, health researchers, and health policymakers as they seek to bridge the "research to practice gap" and improve access to quality treatment for persons suffering from alcoholism. ..
  37. GENETICS OF COCAINE DEPENDENCE
    HENRY RICHARD KRANZLER; Fiscal Year: 2010
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  38. Matching 5-HT Genotypes to Serotonergic Medications for Alcoholism
    GEORGE KENNA; Fiscal Year: 2007
    ....
  39. GENETICS OF COCAINE DEPENDENCE
    Henry Kranzler; Fiscal Year: 2008
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  40. Diffusion, Adoption, and Implementation of Pharmacotherapies in Alcohol Tx
    AMANDA ABRAHAM; Fiscal Year: 2008
    ..This information will be relevant to treatment providers, health researchers, and health policymakers as they seek to bridge the "research to practice gap" and improve access to quality treatment for persons suffering from alcoholism. ..
  41. Novel Approaches to Alcoholism Pharmacotherapy and Risk
    Henry Kranzler; Fiscal Year: 2008
    ..The proposal will also contribute insights into the genetic risk for alcohol dependence and moderators of treatment response, which have implications both for prevention and treatment of the disorder. ..
  42. Matching 5-HT Genotypes to Serotonergic Medications for Alcoholism
    GEORGE KENNA; Fiscal Year: 2008
    ....
  43. GENETICS OF COCAINE DEPENDENCE
    Henry Kranzler; Fiscal Year: 2009
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  44. Matching 5-HT Genotypes to Serotonergic Medications for Alcoholism
    GEORGE KENNA; Fiscal Year: 2009
    ....
  45. Matching 5-HT Genotypes to Serotonergic Medications for Alcoholism
    GEORGE ANTHONY KENNA; Fiscal Year: 2010
    ....
  46. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2007
    ..abstract_text> ..
  47. GENETICS OF COCAINE DEPENDENCE
    Henry Kranzler; Fiscal Year: 2007
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  48. Planning for a CTSA Application at the University of Connecticut
    Judith Fifield; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  49. Novel Approaches to Alcoholism Pharmacotherapy and Risk
    Henry Kranzler; Fiscal Year: 2006
    ..abstract_text> ..
  50. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2003
    ..abstract_text> ..
  51. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2004
    ..abstract_text> ..
  52. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2006
    ..abstract_text> ..
  53. GENETICS OF COCAINE DEPENDENCE
    Henry Kranzler; Fiscal Year: 2006
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  54. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2005
    ..abstract_text> ..
  55. ISOFLAVONE TREATMENT FOR ALCOHOL ABUSE
    Scott Lukas; Fiscal Year: 2008
    ..5) We have collected preliminary data showing that kudzu increases the rate. ..
  56. ISOFLAVONE TREATMENT FOR ALCOHOL ABUSE
    Scott Lukas; Fiscal Year: 2009
    ..5) We have collected preliminary data showing that kudzu increases the rate. ..
  57. Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit
    Kyle Kampman; Fiscal Year: 2008
    ..This research will define ways to make and effectively use such vaccines to stimulate high antibody levels that will have the best chance of success. [unreadable] [unreadable] [unreadable]..
  58. Mentoring in Drug Abuse and Dual Diagnosis Research
    Roger Weiss; Fiscal Year: 2008
    ..Weiss will receive additional training in the areas of 1) chronic pain, 2) brain imaging, and 3) statistics, which will simultaneously strengthen his own research skills and improve his mentoring abilities. ..
  59. Three Methods for Costing Methadone Treatment Services
    GARY ZARKIN; Fiscal Year: 2003
    ..abstract_text> ..
  60. Gabapentin as an Adjunct to Naltrexone for Alcoholism
    Raymond Anton; Fiscal Year: 2002
    ..This evaluation of a novel treatment will allow us to better understand combined pharmacotherapy and develop a new paradigm for medications development for alcoholism. ..
  61. CANNABIS AND SCHIZOPHRENIA: CLOZAPINE VS RISPERIDONE
    Alan Green; Fiscal Year: 2002
    ..If the results of this study confirm the preliminary data, they could suggest a new use for CLOZ, one that could have important public health implications. ..
  62. COMPARISON OF CBT AND MET PLUS NALTREXONE FOR ALCOHOLISM
    Raymond Anton; Fiscal Year: 1999
    ..As such, these results will provide data regarding the types of treatment likely to benefit outpatient alcoholics when applied in other health care settings where issues of clinical acceptability and cost might be consideration. ..
  63. NALTREXONE AND COGNITIVE BEHAVIOR THERAPY OF ALCOHOLISM
    Raymond Anton; Fiscal Year: 1993
    ....
  64. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan Green; Fiscal Year: 2009
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  65. SERTRALINE FOR ALCOHOL DEPENDENCE AND DEPRESSION
    Helen Pettinati; Fiscal Year: 2003
    ..Overall, this project will determine if combining pharmacotherapies results in a better response in comorbidly depressed alcoholics than either medication alone or placebo. ..
  66. Cocaine Withdrawal and Pharmacotherapy Response
    Mehmet Sofuoglu; Fiscal Year: 2007
    ..This proposal, by testing the efficacy of carvedilol and investigating the influence of withdrawal severity on carvedilol's efficacy, may result in development of more effective treatments for cocaine addiction. ..
  67. CTN: Northern New England Node
    Roger Weiss; Fiscal Year: 2008
    ....
  68. BEHAVIORAL SUPPORT WITH PHARMACOTHERAPY FOR ALCOHOLICS
    Helen Pettinati; Fiscal Year: 2003
    ..However, each study site has provided site-specific information on the budget, budget justifications, listing of key personnel, consultant/consortium agreements, and human subjects sections of their respective proposals. ..
  69. Naltrexonel/Acamprosate and CBT/MET Light for Alcoholism
    Raymond Anton; Fiscal Year: 2003
    ..However, each study site has provided site-specific information on the budget, budget justifications, listing of key personnel, consultant/consortium agreements, and human subjects sections of their respective proposals. ..
  70. Cannabis & Schizophrenia: fMRI Reward Circuit Biomaker
    Alan Green; Fiscal Year: 2005
    ..Finding new medications, safer than CLOZ, that may be able to limit cannabis use In patients with SCHIZ is thus of considerable public health relevance. ..
  71. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2003
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  72. Three Methods for Costing Methadone Treatment Services
    GARY ZARKIN; Fiscal Year: 2006
    ..abstract_text> ..
  73. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2004
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  74. Gabapentin as an Adjunct to Naltrexone for Alcoholism
    Raymond Anton; Fiscal Year: 2003
    ..This evaluation of a novel treatment will allow us to better understand combined pharmacotherapy and develop a new paradigm for medications development for alcoholism. ..
  75. Antipsychotics and Alcohol Drinking in Rodents
    Alan Green; Fiscal Year: 2005
    ..The long-term goal of our research is to create better treatments for alcoholism in patients with SCH (and possibly even in those without SCH). ..
  76. RELAPSE PREVENTION GROUP FOR BIPOLAR SUBSTANCE ABUSERS
    Roger Weiss; Fiscal Year: 1999
    ....
  77. Modifying Group Therapy for Bipolar Abusers
    Roger Weiss; Fiscal Year: 2002
    ..If warranted by the results, effect sizes from the proposed study will be used to help in the preparation of a larger-scale subsequent Stage II study. ..
  78. TRAINING IN FUNCTIONAL IMAGING AND ALCOHOL WITHDRAWAL
    DONALD MYRICK; Fiscal Year: 2004
    ....
  79. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  80. Modeling Benefits and Costs of Prison-Based Substance Abuse Treatment
    GARY ZARKIN; Fiscal Year: 2007
    ..2005a). Results will help policy makers make better judgments about the allocation of funding to prison-based drug treatment resources. ..
  81. Modeling Benefits and Costs of Prison-Based Substance Abuse Treatment
    GARY ZARKIN; Fiscal Year: 2009
    ..2005a). Results will help policy makers make better judgments about the allocation of funding to prison-based drug treatment resources. ..
  82. Three Methods for Costing Methadone Treatment Services
    GARY ZARKIN; Fiscal Year: 2005
    ..abstract_text> ..
  83. GABA Medications for Tobacco Addiction
    Mehmet Sofuoglu; Fiscal Year: 2009
    ..The findings of this study will provide valuable information to develop new pharmacotherapies for smoking cessation. ..
  84. COST EFFECTIVENESS OF ALCOHOL TREATMENT
    GARY ZARKIN; Fiscal Year: 2004
    ..abstract_text> ..
  85. CANNABIS AND SCHIZOPHRENIA: CLOZAPINE VS RISPERIDONE
    Alan Green; Fiscal Year: 2003
    ..If the results of this study confirm the preliminary data, they could suggest a new use for CLOZ, one that could have important public health implications. ..